Advertisement

Clinical & Experimental Metastasis

, Volume 24, Issue 3, pp 169–178 | Cite as

A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate

  • Vassilios Vassiliou
  • Christine Kalogeropoulou
  • Efstathia Giannopoulou
  • Michael Leotsinidis
  • Irine Tsota
  • Dimitrios Kardamakis
Research Paper

Abstract

Purpose

To investigate the therapeutic response of patients with different types of bone metastases treated with combined radiotherapy and bisphosphonates.

Patients and methods

By using computed tomography 52 patients were grouped into groups of lytic, mixed and sclerotic bone lesions. All patients were treated with concomitant radiotherapy and ibandronate (10 monthly cycles) and underwent clinical and radiological evaluations prior to therapy and at 3, 6 and 10 months of follow up.

Results

At baseline there were statistically significant differences between the three groups for all the evaluated parameters. From 3 months onwards differences were leveled out. Statistically significant improvements were noted at all time points of evaluation for all groups in parameters such as pain (0–10), quality of life (QOL-physical functioning, 0–100) and Karnofsky performance status (KPS). The average pain score for the lytic group was reduced from 8.1 to 1.5 points at 3 months. The corresponding reductions for the mixed and sclerotic groups were from 6.2 to 0.5 and from 4.4 to 0.3 points respectively. Complete pain responses were >76.4% at all time points for all groups. Opioid consumption was also markedly reduced. Overall, the highest clinical response was noted for the lytic group, even though the mean values of pain, QOL and KPS were worse than those of the two other groups at all time points (apart from pain score at 10 months). The percentage of patients of the lytic group experiencing a complete pain response was the least of the three groups during follow up. At 10 months bone density was almost tripled for the lytic and almost doubled for the mixed group.

Conclusions

Even though the therapeutic outcome for the three groups was similar, the degree of clinical response and reossification differed.

Keywords

Bisphosphonates Bone density Bone metastases Computed tomography Pain Radiotherapy 

References

  1. 1.
    Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(S8):1588–1594PubMedCrossRefGoogle Scholar
  2. 2.
    Sze WM, Shelley MD, Held I, et al (2003) Palliation of metastatic bone pain: single versus multifraction radiotherapy—a systematic review of randomized trials. Clin Oncol 15:345–352CrossRefGoogle Scholar
  3. 3.
    Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321–327PubMedCrossRefGoogle Scholar
  4. 4.
    Hoskin PJ, Stratford NRL, Folkes LK, et al (2000) Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 355:1428–1429PubMedCrossRefGoogle Scholar
  5. 5.
    Body JJ, Diel IJ, Lichinitser MR, et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405PubMedCrossRefGoogle Scholar
  6. 6.
    Pavlakis N, Stocker M (2002) Bisphosphonates for breast cancer. In: The cochrane library, issue 1. Update Software, OxfordGoogle Scholar
  7. 7.
    Rosen L, Gordon D, Tchekmedyian S, et al (2002) Zoledronic acid (Zol) significally reduces skeletal related events in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 21:295Google Scholar
  8. 8.
    Masasachia P, Weinreb M, Balena R, et al (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281–290CrossRefGoogle Scholar
  9. 9.
    Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106PubMedCrossRefGoogle Scholar
  10. 10.
    Rogers MJ, Gordon S, Benford HL, et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978PubMedCrossRefGoogle Scholar
  11. 11.
    Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRefGoogle Scholar
  12. 12.
    Vassiliou V, Kalogeropoulou C, Petsas T, et al (2007) Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between the clinical status of patients and the type of bone metastases? Clin Exp Metastasis (in press) doi:10.1007/s10585-007-9056-zGoogle Scholar
  13. 13.
    Vassiliou V, Kalogeropoulou C, Christopoulos C, et al (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1):264–272PubMedGoogle Scholar
  14. 14.
    Fayers PM, Aaronson NK, Bjordal K, et al (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC Quality of life group, BrusselsGoogle Scholar
  15. 15.
    McQuay HJ, Collins SL, Caroll D, et al (2001) Radiotherapy for the palliation of painful bone metastases (cochrane review). In: The cochrane library. Update software, OxfordGoogle Scholar
  16. 16.
    Falkmer U, Jarhult J, Wersall P, et al (2003) A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 42(5–6):620–633PubMedCrossRefGoogle Scholar
  17. 17.
    Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseus metastases. Final results of the study by the radiation therapy oncology group. Cancer 50:893–899PubMedCrossRefGoogle Scholar
  18. 18.
    Salazar OM, Sandhut T, da Motta MW, et al (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the international atomic energy agency (IAEA). Int J Radiat Oncol Biol Phys 50(3):765–775PubMedCrossRefGoogle Scholar
  19. 19.
    Body JJ, Diel IJ, Bell R, et al (2004) Oral ibandronate improved pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312PubMedCrossRefGoogle Scholar
  20. 20.
    Diel IJ, Body JJ, Lichinitser MR, et al (2004) Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712PubMedCrossRefGoogle Scholar
  21. 21.
    Kouloulias EV, Kouvaris RJ, Antypas C, et al (2003) An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther Onkol 179:471–479PubMedGoogle Scholar
  22. 22.
    Kouloulias V, Matsopoulos G, Kouvaris J, et al (2003) Radiotherapy in conjuction with intravenous infusion of 180mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 57(1):143–157PubMedCrossRefGoogle Scholar
  23. 23.
    Firusian N, Mellin P, Schmidt CG (1976) Results of 89-strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report. J Urol 116:764PubMedGoogle Scholar
  24. 24.
    Quilty PM, Kirk D, Bolger JJ, et al (1994) A comparison of the palliative effects of strontium 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33PubMedCrossRefGoogle Scholar
  25. 25.
    Buchali K, Correns HJ, Schuerer M, et al (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14:349PubMedCrossRefGoogle Scholar
  26. 26.
    Reddy EK, Robinson RG, Mansfield CM (1986) Strontium 89 for palliation of bone metastases. J Natl Med Assoc 78:27PubMedGoogle Scholar
  27. 27.
    Storto G, Klain M, Paone G, et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRefGoogle Scholar
  28. 28.
    Blitzer P (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 55:1468–1472PubMedCrossRefGoogle Scholar
  29. 29.
    Ratanatharathorn V, Powers WE, Moss WT, et al (1999) Bone metastases: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 44:1–18PubMedCrossRefGoogle Scholar
  30. 30.
    Wu JS, Wong R, Johnson M, et al (2003) Meta-analysis of the dose fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605PubMedCrossRefGoogle Scholar
  31. 31.
    Osoba D, Rodrigues G, Myles J, et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMedGoogle Scholar
  32. 32.
    Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11:1699–1707PubMedGoogle Scholar
  33. 33.
    Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(Suppl 3):834–839PubMedCrossRefGoogle Scholar
  34. 34.
    Chow E, Holden L, Rubenstein J, et al (2004) Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy—a feasibility study. Radiother Oncol 70:291–294PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  • Vassilios Vassiliou
    • 1
  • Christine Kalogeropoulou
    • 2
  • Efstathia Giannopoulou
    • 3
  • Michael Leotsinidis
    • 4
  • Irine Tsota
    • 2
  • Dimitrios Kardamakis
    • 1
  1. 1.Department of Radiation OncologyUniversity of Patras Medical SchoolPatrasGreece
  2. 2.Department of RadiologyUniversity of Patras Medical SchoolPatrasGreece
  3. 3.Laboratory of Clinical OncologyUniversity of Patras Medical SchoolPatrasGreece
  4. 4.Laboratory of Public HealthUniversity of Patras Medical SchoolPatrasGreece

Personalised recommendations